Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.

Ubink I, Bolhaqueiro ACF, Elias SG, Raats DAE, Constantinides A, Peters NA, Wassenaar ECE, de Hingh IHJT, Rovers KP, van Grevenstein WMU, Laclé MM, Kops GJPL, Borel Rinkes IHM, Kranenburg O.

Br J Surg. 2019 Sep;106(10):1404-1414. doi: 10.1002/bjs.11206. Epub 2019 Jun 14.

2.

Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures.

van der Waals LM, Laoukili J, Jongen JMJ, Raats DA, Borel Rinkes IHM, Kranenburg O.

Sci Rep. 2019 Jan 28;9(1):819. doi: 10.1038/s41598-018-37316-w.

3.

CD95 ligand induces senescence in mismatch repair-deficient human colon cancer via chronic caspase-mediated induction of DNA damage.

Raats DA, Frenkel N, van Schelven SJ, Rinkes IH, Laoukili J, Kranenburg O.

Cell Death Dis. 2017 Mar 16;8(3):e2669. doi: 10.1038/cddis.2017.87.

4.

Mice lacking functional CD95-ligand display reduced proliferation of the intestinal epithelium without gross homeostatic alterations.

Trumpi K, Steller EJ, de Leng WW, Raats DA, Nijman IJ, Morsink FH, Borel Rinkes IH, Kranenburg O.

Med Mol Morphol. 2016 Jun;49(2):110-8. doi: 10.1007/s00795-015-0129-9. Epub 2015 Dec 23.

PMID:
26700225
5.

PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells.

Steller EJ, Raats DA, Koster J, Rutten B, Govaert KM, Emmink BL, Snoeren N, van Hooff SR, Holstege FC, Maas C, Borel Rinkes IH, Kranenburg O.

Neoplasia. 2013 Feb;15(2):204-17.

6.

Intravital microscopy through an abdominal imaging window reveals a pre-micrometastasis stage during liver metastasis.

Ritsma L, Steller EJ, Beerling E, Loomans CJ, Zomer A, Gerlach C, Vrisekoop N, Seinstra D, van Gurp L, Schäfer R, Raats DA, de Graaff A, Schumacher TN, de Koning EJ, Rinkes IH, Kranenburg O, van Rheenen J.

Sci Transl Med. 2012 Oct 31;4(158):158ra145. doi: 10.1126/scitranslmed.3004394.

7.

The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion.

Steller EJ, Ritsma L, Raats DA, Hoogwater FJ, Emmink BL, Govaert KM, Laoukili J, Rinkes IH, van Rheenen J, Kranenburg O.

EMBO Rep. 2011 Sep 1;12(9):931-7. doi: 10.1038/embor.2011.129.

8.

Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.

De Bruijn MT, Raats DA, Tol J, Hinrichs J, Teerenstra S, Punt CJ, Rinkes IH, Kranenburg O.

Anticancer Res. 2011 Apr;31(4):1379-85.

PMID:
21508389
9.

Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737.

Raats DA, de Bruijn MT, Steller EJ, Emmink BL, Borel-Rinkes IH, Kranenburg O.

Cell Oncol (Dordr). 2011 Aug;34(4):307-13. doi: 10.1007/s13402-011-0026-8. Epub 2011 Apr 6.

PMID:
21468686
10.

Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation.

van Houdt WJ, Hoogwater FJ, de Bruijn MT, Emmink BL, Nijkamp MW, Raats DA, van der Groep P, van Diest P, Borel Rinkes IH, Kranenburg O.

Neoplasia. 2010 Jun;12(6):443-52.

11.

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa.

de Bruijn MT, Raats DA, Hoogwater FJ, van Houdt WJ, Cameron K, Medema JP, Borel Rinkes IH, Kranenburg O.

Br J Cancer. 2010 Apr 13;102(8):1254-64. doi: 10.1038/sj.bjc.6605633. Epub 2010 Mar 30.

12.

Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells.

Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF, Raats DA, Sprick MR, Schaefer U, Van Houdt WJ, De Bruijn MT, Schackmann RC, Derksen PW, Medema JP, Walczak H, Borel Rinkes IH, Kranenburg O.

Gastroenterology. 2010 Jun;138(7):2357-67. doi: 10.1053/j.gastro.2010.02.046. Epub 2010 Feb 23.

PMID:
20188103

Supplemental Content

Loading ...
Support Center